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Associations between Use of Antimalarial Medications and Health among U.S. Veterans of the
Wars in Iraq and Afghanistan
Aaron I. Schneiderman,1* Yasmin S. Cypel,1 Erin K. Dursa,1 and Robert M. Bossarte2
1

Department of Veterans Affairs, Epidemiology Program, Post Deployment Health Services (10P4Q), Ofﬁce of Patient Care Services, Veterans
Health Administration, Washington, District of Columbia; 2Department of Behavioral Medicine and Psychiatry, West Virginia University Injury
Control Research Center, West Virginia University School of Medicine, Morgantown, West Virginia

Abstract. Meﬂoquine (Lariam®; Roche Holding AG, Basel, Switzerland) has been linked to acute neuropsychiatric side
effects. This is a concern for U.S. veterans who may have used meﬂoquine during recent Southwest Asia deployments.
Using data from the National Health Study for a New Generation of U.S. Veterans, a population-based study of U.S.
veterans who served between 2001 and 2008, we investigated associations between self-reported use of antimalarial
medications and overall physical and mental health (MH) using the twelve-item short form, and with other MH outcomes
using the post-traumatic stress disorder Checklist-17 and the Patient Health Questionnaire (anxiety, major depression,
and self-harm). Multivariable logistic regression was performed to examine associations between health measures and
seven antimalarial drug categories: any antimalarial, meﬂoquine, chloroquine, doxycycline, primaquine, meﬂoquine plus
any other antimalarial, and any other antimalarial or antimalarial combination while adjusting for the effects of deployment
and combat exposure. Data from 19,487 veterans showed that although antimalarial use was generally associated with
higher odds of negative health outcomes, once deployment and combat exposure were added to the multivariable
models, the associations with each of the MH outcomes became attenuated. A positive trend was observed between
combat exposure intensity and prevalence of the ﬁve MH outcomes. No signiﬁcant associations were found between
meﬂoquine and MH measures. These data suggest that the poor physical and MH outcomes reported in this study
population are largely because of combat deployment exposure.

INTRODUCTION

irritable bowel syndrome and inﬂammatory bowel disease has
also been suggested17; GI tolerability is usually improved with
administration of enteric-coated forms of doxycycline hyclate,
a main form of doxycycline,18 or with use of its monohydrate
derivative.13 For chloroquine, the most serious side effects
noted include retinopathy,4,19–22 cardiomyopathy,4,22 myopathy,22 and neuromyopathy.4,22 Primaquine has a long history
of use and is effective against the various life stages of the
Plasmodium species, the malarial parasites, but carries the
signiﬁcant danger of hemolysis in glucose-6-phosphate
dehydrogenase–deﬁcient populations.23 Besides its effect
on red blood cell metabolism, another adverse consequence
of primaquine use is GI upset.24
Meﬂoquine use has been linked to reports of acute neuropsychiatric side effects in both civilian and military
populations,25–32 particularly in those with a history of psychiatric disorders.29,33,34 The package insert for meﬂoquine
advises against prescribing it to individuals with a psychiatric
disorder or a history of seizures because of product safety
concerns based on case reports and clinical studies. This has
led to the addition by the manufacturer of a U.S. Food and
Drug Administration black-box package warning in 2013 that
addresses acute neuropsychiatric effects and the possibility
of persistent or permanent neurologic health outcomes.35
Concerns over acute and potential long-term effects from the
use of meﬂoquine in military personnel have resulted in DoD
policy changes prioritizing the selection of other chemoprophylactic agents in place of meﬂoquine during recent military
conﬂicts.6,11,12 Meﬂoquine’s neuropsychiatric effects may
occur through the inhibition of neurotransmitters such as
acetylcholinesterase.36
Overall, the burden of mental health (MH) disorders among
veterans of the U.S. military engagements in Afghanistan
(Operation Enduring Freedom [OEF]) and Iraq (Operation Iraqi
Freedom [OIF]) has been a signiﬁcant concern for Veterans
Affair and DoD and a signiﬁcant driver of health-care

The relationship between antimalarial medications used
for chemoprophylaxis and a range of adverse outcomes is
documented by case reports and survey studies; however,
ﬁndings and estimates of risk associated with malaria chemoprophylaxis have been inconsistent and frequently poorly
deﬁned.1,2 The adverse outcomes reported and investigated
are most notably dermatological, gastrointestinal (GI), and
neuropsychiatric (e.g., includes both central and peripheral
nervous system disorders such as headache and dizziness,
and psychiatric disorders such as anxiety and depression).3–5
The importance and impact of the possible side effects of
antimalarial medication is especially signiﬁcant for more than
2.7 million U.S. military service members and veterans who
served in Southwest Asia and other countries with endemic
malaria.6–8 During this time, recognition of the potential side
effects proﬁles for some medications, speciﬁcally meﬂoquine
(Lariam®; Roche Holding AG, Basel, Switzerland), has resulted
in changes to U.S. Department of Defense (DoD) policy and
prescribing practices.9,10
Antimalarial drug proﬁles, military operational requirements,
and the regional presence of drug-resistant malaria strains are
all factors that guide policy and practice regarding the use of
speciﬁc chemoprophylactic agents.6,11,12 The medications
that satisfy policy and prevention requirements may have
known side effects that inﬂuence prescribing practices and
adherence. Doxycycline is well tolerated when used for prophylaxis, but GI complaints and photosensitivity are common
side effects,13–16 and an increased risk for development of
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utilization.37–39 Both epidemiological research and healthcare utilization ﬁgures demonstrate the high level of MH diagnoses and symptoms among these military personnel and
veterans that stem from deployment-related exposures. The
potential for neuropsychiatric effects from the administration
of meﬂoquine may be related to a concomitant increase in MH
concerns, including post-traumatic stress disorder (PTSD),
anxiety disorders, depression, and suicide.40
This study examines whether the use of meﬂoquine and
other antimalarial medications in a population of OEF/OIF
veterans is associated with self-reported MH conditions and
measures of functional health status, while considering the
independent effects of deployment and combat exposure.
MATERIALS AND METHODS
Study population. The Department of Veterans Affairs (VA)
2009–2011 National Health Study for a New Generation of U.S.
Veterans (“NewGen”) study sampled 30,000 OEF/OIF veterans (deployed) and 30,000 non-OEF/OIF veterans who
served in the military between October 2001 and June 2008
(nondeployed), including veterans in the reserves or National
Guard who had not separated from these military components. The sample (N = 60,000) was selected from a sample
frame generated from data ﬁles provided by the DoD Defense
Manpower Data Center and the VA/DoD Identiﬁcation Repository database and was stratiﬁed by branch of service (Air
Force, Army, Marines, and Navy), unit component (active duty,
reserve, or National Guard), and gender. A 20% oversample
for women was included to achieve adequate panel representation.41 Survey data were collected between 2009 and
2011 using tailored design methodology for mail, telephone,
and web-based modes.42 The response rate was 34.3% (N =
20,563).41 The study was approved by the Washington DC VA
Medical Center Institutional Review Board.
Antimalarial use. Respondents were asked whether they
ever took medications to prevent malaria during their military
service and if “yes,” marked the type of antimalarial taken based
on the following response options: meﬂoquine, chloroquine
(Aralen®; Sanoﬁ Aventis, Bridgewater, NJ), doxycycline
(Vibramycin®; Pﬁzer, Inc., New York, NY), primaquine, or “other.”
When possible, “other” responses were recoded into existing
options. All responses were then classiﬁed depending on
whether use of a single drug was reported or if multiple antimalarials were used. The resultant antimalarial classiﬁcation used
for analyses consisted of meﬂoquine, chloroquine, doxycycline,
primaquine, meﬂoquine used with other antimalarials (a history of
using two or three different drugs), and other antimalarials
(a single antimalarial and a history of two or three different drugs,
excluding meﬂoquine combinations), and drug type not speciﬁed. For any reports of multiple antimalarials (sometimes referred
to as “combinations”), no data on whether they were administered together or at different times were collected. Except for
reports of four or more antimalarials used, all combinations of
meﬂoquine use were examined (reports of meﬂoquine and other
antimalarials) because of its possible association with neuropsychiatric symptoms.25–32,40,43–46 Antimalarial drug status was
based on the survey questions described previously and deﬁned
on three levels: whether an antimalarial drug was taken but not
speciﬁed (“unknown” type), one or more speciﬁc drugs were
taken (“known” type), or no drugs were taken. Antimalarial drug
use was speciﬁed as either used or not used.
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Combat exposure. An individual’s exposure to military
combat was assessed based on a dichotomous response
(yes/no) to three survey questions adapted from the DoD Post
Deployment Health Assessment form (DD 2796): “Did you ever
feel that you were in great danger of being killed?” “Did you see
anyone wounded, killed, or dead?” “Were you engaged in
direct combat where you discharged your weapon?”47 Summary scores were created that ranged from 0 to 3 where increasing scores represented increasing combat exposure
intensity. The internal consistency of these items was
assessed using Cronbach’s alpha.48
Health outcome measures and indices. Mental and
physical health outcomes were based on responses to items
included in the NewGen questionnaire. Mental and physical
health component scores were determined using the Medical
Outcomes Study twelve-item short form (SF-12)49 to assess
overall mental and physical health that can be compared with
national U.S. norms having a mean (± standard deviation) of 50
(±10). A positive outcome for PTSD was determined based on
scores from the 17-item PTSD checklist (PCL-C).50 A PCL
cutoff of 50 or higher was used to identify those screening
positive for PTSD. 37,51 Scales from the self-administered
version of the Patient Health Questionnaire (PHQ),52 were
scored for major depression, thoughts of death or self-harm,
and other anxiety disorders. Six health indices were examined
in total (SF-12 Composite Mental Health Score, SF-12 Composite Physical Health Score, PTSD, thoughts of death/selfharm, other anxiety disorders, and major depression).
Deployment status and other individual characteristics.
Sociodemographic and military service characteristics were
included in statistical models. Self-reported deployment to
OEF/OIF (deployed/not deployed) and sample frame data for
branch of service (Army, Air Force, Marine Corps, and Navy)
and service component (active duty, reserve, National Guard)
were examined. The sociodemographic characteristics were
gender, age group (24–34, 35–44, 45–54, and ³ 55), education
(high school/General Equivalency Diploma, some college/associate’s degree, bachelor’s degree, or higher), race/ethnicity (nonHispanic white, non-Hispanic black, Hispanic, Asian, American
Indian or Alaska native, native Hawaiian/Paciﬁc Islander, other),
current household income (< $35,000, $35,000–49,999, $50,000–
74,999, $75,000–99,999, $100,000–149,999, and ³ $150,000),
current employment status (yes/no), and marital status (married, separated/divorced, widowed, and never married/single).
All the sociodemographic data, except for age, were based on
self-reports; age data were obtained from the sample frame.
Statistical analyses. SAS® software version 9.4 (SAS Institute, Inc., Cary, NC) was used to generate all statistical
output.53 Cross-tabulations for each of the sociodemographic
and military service characteristics with antimalarial drug
status were completed to describe sample characteristics and
preliminary associations among deployment status, antimalarial use, and health outcomes. χ2 statistics were generated to
check for statistical signiﬁcance of these associations. Means
and their standard errors were computed for the SF-12 composite mental and physical health scores by deployment
status and within deployment status by all categories of antimalarial drug use. Dichotomous outcome variables were
created; individuals’ SF-12 composite scores were coded as
either 1 (above U.S. mean) or 0 (below mean).
Multivariable logistic regression was used to examine associations between each of the six health indices (dependent
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variables) and seven antimalarial drug categories (any antimalarial, meﬂoquine, chloroquine, doxycycline, primaquine,
meﬂoquine plus any other antimalarial, and any other antimalarial or combination of antimalarials; “type not speciﬁed”
was excluded) while controlling for sociodemographic and
military service characteristics. Three models were examined
to better understand the independent effects of deployment
and combat exposure on the association between health
outcome and antimalarial drug use. Model 1 (“demographic”)
examined the relationship between health outcome and antimalarial drug use while controlling for gender, age group,
education, race/ethnicity, income, employment status, marital
status, component, and branch of service. Model 2 (“deployment”) examined the relationship between health outcome and antimalarial drug use but added deployment as an
independent variable and a ﬁrst-order interaction term
(deployment × antimalarial). Model 3 (“combat exposure”)
paralleled model 2 except that combat exposure was added.
Interaction terms were tested for signiﬁcance and dropped
from models if found not to be statistically signiﬁcant; if associations between health outcome and antimalarial drug
differed signiﬁcantly when stratiﬁed by deployment status,
they were reported separately. Adjusted odds ratios (AORs)
and 95% conﬁdence intervals (CIs) are reported for each of
the three models by outcome and antimalarial drug. Each of
these three regressions modeled the odds of having SF-12
composite scores fall below the U.S. mean versus the odds
of having scores above the U.S. mean. When PTSD, suicide,
other anxiety, and major depression were used as outcome
variables, we modeled the odds of having the condition
versus the odds of not having the condition.
To extend interpretation of selected regression ﬁndings,
bivariate analyses were performed among the deployed to
further examine the relationship between combat intensity
score and health outcomes among those who reported antimalarial use and those who did not.
Survey responses were weighted to account for nonresponse. The resultant weights were modiﬁed using a poststratiﬁcation approach to reduce bias resulting from the
misclassiﬁcation of deployment in the sampling frame.54,55 All
statistics reported, except for counts, were weighted.
RESULTS
Of 20,563 respondents, a total of 1,076 individuals were
excluded from analysis based on responses to antimalarial
medication use during military service: “don’t know” (N = 150),
failure to endorse any selection (N = 818), endorsement of
four or more antimalarials (N = 91), and self-reporting nonantimalarial drugs (N = 17). The ﬁnal analytical sample contained 19,487 individuals.
Table 1 provides descriptive statistics on demographic and
service characteristics by reported antimalarial use. A majority
(N = 11,100; 61.4%) of veterans reported receiving no antimalarial drugs, whereas 23.5% (N = 4,952) reported receiving
these medications but did not provide medication information.
Another 3,435 participants (15.1%) reported receiving an antimalarial and could identify the medication. Of those endorsing one or more antimalarials, doxycycline (45.2%),
meﬂoquine (alone or reported with other antimalarials, 23.3%),
and chloroquine (10.4%) were the most frequently reported
(not shown in tables).

Chi-square tests of association for each respondent characteristic by antimalarial drug status were statistically signiﬁcant (P < 0.0001) (Table 1). Use of antimalarial medication was
more frequently reported by males than by females and was
more prevalent among participants aged 35 years and older
when compared with those who did not report receiving antimalarial medications. Participants who reported receiving
one or more speciﬁc antimalarial medications were more likely
to report their race as non-Hispanic white (76.2%) when
compared with those who reported no antimalarial use
(70.0%) or an unknown type of antimalarial medication (70.5%).
Antimalarial use (i.e., known or unknown type) was more
prevalent among those who served in the Army (56.9%) than
among those who served in the Marine Corps (15.3%), Air
Force (15.1%), or Navy (12.7%) (not reported in tables). Those
who deployed to Iraq or Afghanistan were more likely to report
receiving some form of antimalarial medication (known or unknown type) than those who were not deployed (76.1% and
23.9%, respectively) (not reported in tables).
Statistics on the prevalence of participants reporting poor
physical and MH (SF-12), endorsement of thoughts of death or
self-harm or positive screens for PTSD, other anxiety disorders, and major depression are in Table 2. Among deployed
participants, those who received an antimalarial were more
likely than those who did not use an antimalarial to report
higher prevalence of all six health outcomes included in this
study. Speciﬁcally, 53.6% of the deployed sample who reported antimalarial use had an SF-12 MH component score
below the U.S. mean (no use = 47.3%), 43.5% had an SF-12
physical health component score below the U.S. mean (no
use = 36.2%), 18.5% screened positive for symptoms of
PTSD (no use = 11.3%), 11.7% endorsed thoughts of death or
self-harm (no use = 8.8%), 12.5% screened positive for
symptoms of other anxiety disorders (no use = 8.2%), and
11.5% screened positive for major depression (no use =
8.1%). There was little variability in the prevalence of outcomes across speciﬁc antimalarial agents, except for primaquine which had the lowest reported prevalence across
measured health indices.
When comparing across outcomes (Table 2) among the
deployed, participants who reported receiving chloroquine
reported the highest prevalence of poor physical health and
MH (SF-12); those who reported receiving meﬂoquine and any
other antimalarial (chloroquine, doxycycline, or primaquine)
had the highest prevalence of positive screens for PTSD, other
anxiety disorders, and major depression. The one exception to
this pattern was for those who reported taking primaquine
alone, which had the lowest reporting for both use (1.4%) and
reported mental and physical health outcomes (SF-12 MH
component score, 41.0%; SF-12 physical health component
score, 28.7%; PTSD, 6.9%; thoughts of death/self-harm, 6.3%;
other anxiety disorders, 1.4%; and major depression, 3.3%).
Relationships between prevalence of adverse outcomes
and antimalarial use status among the nondeployed sample
were not consistent with those observed among the deployed
(Table 2). The nondeployed sample who endorsed antimalarial
use reported higher prevalence of poor physical health (53.9%
versus 40.3% with no use), screened positive for other anxiety
disorders (9.8% versus 8.6% with no use) and major depression (8.9% versus 8.6%). Further comparison of the
nondeployed reporting no antimalarial use to those reporting
antimalarial use showed nonusers had higher prevalence of
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TABLE 1
Sociodemographic and military service characteristics of survey respondents by antimalarial drug status (N = 19,487): National Health Study for a
New Generation of U.S. Veterans
Antimalarial drug status‡
Reported receiving drug(s), but none speciﬁed
(N = 4,952; 23.5%)

Reported receiving no drugs
(N = 11,100; 61.4%)

−−−−n§ (%k)−−−−

Characteristic*†

Gender‡
Males
Females
Age group{
24–34
35–44
45–54
³ 55
Education‡
High school/GED
Some college/AA**
College or more
Race/ethnicity‡#
Non-Hispanic white
Non-Hispanic black
Hispanic
Asian
American Indian or Alaska native
Native Hawaiian or Paciﬁc Islander
Other
Current household income‡
< $35,000
$35,000–49,999
$50,000–74,999
$75,000–99,999
$100,000–149,999
³ $150,000
Currently used for wages‡ (% yes)
Marital status‡
Married
Separated/divorced
Widowed
Never married/single
Service component{
Active duty
Reserve
National guard
Branch of service{
Army
Air Force
Marine Corps
Navy
Deployment to OEF/OIF‡ (% yes)
Combat exposure intensity††
0
1
2
3

Reported receiving one or more drugs
(N = 3,435; 15.1%)

4,233 (90.6)
719 (9.4)

2,837 (89.5)
598 (10.5)

8,288 (79.9)
2,812 (20.1)

1,719 (46.0)
1,247 (23.4)
1,461 (23.8)
525 (6.8)

1,215 (46.8)
1,000 (26.7)
928 (21.2)
292 (5.3)

5,541 (64.1)
2,489 (18.2)
2,280 (14.1)
790 (3.6)

787 (18.3)
2,443 (53.2)
1,705 (28.5)

350 (12.6)
1,529 (50.6)
1,550 (36.8)

1,744 (19.4)
5,585 (54.3)
3,744 (26.3)

3,438 (70.5)
638 (12.2)
486 (9.8)
90 (1.9)
40 (0.8)
38 (0.8)
186 (4.0)

2,596 (76.2)
336 (9.3)
228 (6.8)
63 (1.9)
24 (0.8)
16 (0.5)
151 (4.7)

7,730 (70.0)
1,476 (12.7)
973 (9.1)
223 (2.0)
73 (0.8)
70 (0.6)
501 (4.9)

1,072 (26.6)
834 (17.9)
1,152 (23.0)
746 (13.9)
764 (13.3)
318 (5.3)
3,141 (62.2)

599 (22.2)
515 (16.9)
810 (24.5)
549 (14.1)
600 (14.9)
330 (7.3)
1,999 (56.8)

3,119 (35.3)
1,936 (18.4)
2,449 (20.8)
1,519 (11.7)
1,346 (9.8)
588 (4.0)
6,604 (58.1)

3,525 (68.6)
694 (13.6)
21 (0.3)
698 (17.4)

2,426 (68.9)
504 (13.9)
7 (0.2)
489 (16.9)

7,130 (60.7)
1,640 (14.2)
32 (0.2)
2,261 (24.9)

2,035 (55.3)
1,586 (22.1)
1,331 (22.6)

1,223 (50.0)
1,289 (25.1)
923 (24.8)

4,184 (53.7)
3,875 (26.4)
3,041 (20.0)

2,915 (55.3)
823 (14.9)
579 (15.5)
635 (14.4)
3,706 (71.6)

2,117 (59.3)
605 (15.4)
385 (15.0)
328 (10.2)
2,944 (83.3)

5,540 (45.0)
2,702 (22.8)
886 (10.7)
1,972 (21.5)
5,806 (42.8)

1,072 (23.4)
977 (21.3)
1,202 (27.1)
1,062 (28.2)

576 (16.9)
709 (20.6)
1,001 (29.6)
899 (33.0)

4,316 (56.2)
1,811 (21.3)
1,193 (13.7)
677 (8.9)

OEF = Operation Enduring Freedom (Afghanistan); OIF = Operation Iraqi Freedom (Iraq).
* Sum of counts may not always equal total because of missing values.
† Association between each of the sociodemographic and antimalarial drug status is statistically signiﬁcant (P < 0.0001) based on the χ2 test statistic.
‡ Self-reported.
§ Sample size (unweighted).
k Percent (weighted).
{ Obtained from sampling frame.
# “Other” race/ethnicity represents those who reported themselves as some combination of race and/or ethnicity or undeﬁned.
** Associate of Arts Degree.
†† Combat exposure intensity is the sum of a positive response on 3 questionnaire items (ever felt in great danger of being killed; ever seen anyone wounded, killed or dead; ever engaged in direct
combat where you discharged your weapon). Scores range from 0 (not exposed) to 3 (most exposed).

poor MH (SF-12; 45.2%, no use versus 42.5%, use), positive
PTSD screen (12.7% versus 10.1%), or reported thoughts of
death or self-harm (10.3% versus 10.1%). The highest prevalence of poor SF-12 MH Composite Score among the nondeployed was reported by those who did not endorse
antimalarial use. Participants who were unable to provide information on the antimalarial used had the highest prevalence

of positive screens for PTSD compared with other singly used
antimalarials or antimalarial combinations.
Comparisons of study outcomes provide evidence of relationships between antimalarial use and deployment. When all
those who reported antimalarial use were compared on deployment status, the deployed reported higher prevalence
than the nondeployed for poor MH (SF-12; 53.6% versus
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TABLE 2
OEF/OIF deployment status and antimalarial drug use (N = 19,487) for selected health outcomes: National Health Study for a New Generation of
U.S. Veterans
Selected health outcomes*
All (N = 19,487)
OEF/OIF deployment status, antimalarial
drugs received during military service*

Deployed
Antimalarial drug use
Meﬂoquine
Chloroquine
Doxycycline
Primaquine
Meﬂoquine + “X”‡
Other antimalarials
Type not speciﬁed
No use
Nondeployed
Antimalarial drug use
Meﬂoquine
Chloroquine
Doxycycline
Primaquine
Meﬂoquine + “X”‡
Other antimalarials
Type not speciﬁed
No use

SF-12 mental health
score (below U.S. mean)

SF-12 physical health
score (below U.S. mean)

PTSD

Thoughts of
death/self-harm

Other anxiety

Major depression

n (%)

(%)

Mean (SEM)†

(%)

Mean (SEM)†

(%)

(%)

(%)

(%)

12,456 (55.7)
6,650 (52.8)
307 (4.4)
274 (3.5)
1,315 (20.5)
98 (1.4)
425 (6.0)
525 (7.0)
3,706 (57.2)
5,806 (47.2)
7,031 (44.3)
1,737 (20.8)
39 (2.2)
110 (5.8)
141 (8.8)
35 (1.6)
52 (2.8)
114 (6.3)
1,246 (72.5)
5,294 (79.2)

50.7
53.6
51.5
57.7
53.3
41.0
53.0
47.2
54.8
47.3
44.6
42.5
33.9
37.2
41.4
40.7
36.8
41.0
43.7
45.2

46.7 (0.13)
45.8 (0.18)
45.6 (0.90)
46.1 (0.73)
46.1 (0.39)
49.0 (1.15)
45.0 (0.80)
47.6 (0.61)
45.5 (0.24)
47.6 (0.18)
48.3 (0.17)
48.7 (0.35)
52.2 (2.04)
50.6 (1.06)
49.1 (1.07)
50.8 (2.06)
49.9 (1.65)
48.7 (1.56)
48.4 (0.43)
48.1 (0.19)

40.0
43.5
38.1
51.8
39.3
28.7
44.1
44.6
45.1
36.2
43.2
53.9
49.0
47.7
40.9
42.8
51.2
58.6
56.1
40.3

49.5 (0.11)
48.8 (0.15)
51.0 (0.58)
46.4 (0.79)
49.8 (0.30)
51.0 (0.99)
48.4 (0.65)
48.3 (0.55)
48.4 (0.20)
50.2 (0.15)
48.6 (0.15)
46.1 (0.32)
48.8 (1.67)
47.8 (1.23)
49.3 (1.16)
47.6 (2.39)
45.7 (1.57)
46.0 (1.14)
45.5 (0.38)
49.2 (0.17)

15.1
18.5
14.2
18.9
17.9
6.9
20.0
17.8
19.3
11.3
10.6
10.1
7.5
7.4
11.1
3.0
9.7
13.3
13.7
12.7

10.3
11.7
14.0
12.8
10.9
6.3
10.7
10.9
12.1
8.8
10.3
10.1
7.0
9.2
10.5
5.9
7.5
15.0
9.9
10.3

10.5
12.5
10.8
10.4
11.2
1.4
15.3
12.1
13.3
8.2
8.9
9.8
5.7
2.5
7.1
11.0
7.3
11.2
10.8
8.6

9.9
11.5
9.3
11.4
9.8
3.3
12.5
12.0
12.4
8.1
8.6
8.9
3.3
4.5
9.1
3.2
4.3
11.2
9.4
8.6

OEF = Operation Enduring Freedom (Afghanistan); OIF = Operation Iraqi Freedom (Iraq); PTSD = post-traumatic stress disorder.
* Self-reported; n (unweighted), % (weighted).
† Standard error of the mean.
‡ X = 1 or 2 other antimalarials reported.

42.5%), thoughts of death or self-harm (11.7% versus 10.1%),
positive screens for PTSD (18.5% versus 10.1%), other anxiety disorders (12.5% versus 9.8%), and major depression
(11.5% versus 8.9%). Relationships between outcome prevalence and deployment were less clear for those reporting no
antimalarial use.
Table 3 contains the AORs obtained from the logistic regression models that had no signiﬁcant ﬁrst-order interaction
terms, whereas Table 4 contains the AORs based on models
that did. When controlling for demographic and military service characteristics alone (model 1, “demographics”), the
odds are elevated for ﬁnding a negative health outcome
among those taking any antimalarial medications compared
with the odds for those not taking any antimalarial medications. Statistically signiﬁcant elevated odds ratios (ORs) were
found for poor MH (AOR = 1.39, 95% CI: 1.29–1.49), poor
physical health (AOR = 1.23, 95% CI: 1.14–1.32), positive
screen for PTSD (AOR = 1.83, 95% CI: 1.64–2.04), thoughts of
death or self-harm (AOR = 1.31, 95% CI: 1.16–1.47), or positive screens for other anxiety disorders (AOR = 1.56, 95% CI:
1.38–1.76) and major depression (AOR = 1.45, 95% CI:
1.28–1.65). The addition of deployment as an independent
variable had little effect on estimates. However, the addition of
combat exposure resulted in the loss of statistical signiﬁcance
for all observed relationships.
Chloroquine showed signiﬁcant elevated ORs for poor
overall MH (SF-12) in models 1 and 2 (demographic and deployment, respectively: AOR = 1.33, 95% CI: 1.05–1.70;
AOR = 1.30, 95% CI: 1.03–1.66) for users versus nonusers.
These relationships were no longer signiﬁcant when combat
exposure was added in model 3 (AOR = 1.15, 95% CI:
0.88–1.50).
Signiﬁcant elevated associations between doxycycline use
and poor MH outcome were shown in the demographic model

(AOR = 1.21, 95% CI: 1.07–1.37) and with a positive screen for
PTSD in the demographic (AOR = 1.38, 95% CI: 1.15–1.65)
and deployment models (AOR = 1.22, 95% CI: 1.02–1.47). In
model 3, the AORs for poor overall MH and PTSD weakened
and lost statistical signiﬁcance (AOR = 0.96, 95% CI:
0.83–1.09 and AOR = 0.96, 95% CI: 0.79–1.15, respectively).
No signiﬁcant associations were found for meﬂoquine use
for the MH and physical health outcomes, a ﬁnding that continued across the three models. Adjusted odds ratios ranged
for model 1 from 0.86 (95% CI: 0.54–1.36—major depression)
to 1.36 (95% CI: 0.92–2.01—thoughts of death/self-harm),
whereas for model 3, ORs dropped with no change in signiﬁcance. Reported meﬂoquine and any other antimalarial use
resulted in signiﬁcant, elevated associations with a positive
screen for PTSD and other anxiety disorders in the demographic (PTSD: AOR = 1.63, 95% CI: 1.20–2.20; other
anxiety: AOR = 1.63, 95% CI: 1.17–2.27) and deployment
models (PTSD: AOR = 1.45, 95% CI: 1.07–1.97; other anxiety:
AOR = 1.53, 95% CI: 1.10–2.14), whereas adjustment for
combat exposure in model 3 resulted in further decreases and
nonsigniﬁcance in the AORs (PTSD: AOR = 1.09, 95% CI:
0.79–1.50 (Table 3); other anxiety, among deployed: AOR =
1.26, 95% CI: 0.88–1.81) (Table 4).
Reports of any other antimalarial or antimalarials showed
signiﬁcant elevated associations with poor physical health
(AOR = 1.23, 95% CI: 1.02–1.49), positive screens for PTSD
(AOR = 1.63, 95% CI: 1.24–2.13), thoughts of death or selfharm (AOR = 1.42, 95% CI: 1.03–1.96), or positive screens for
other anxiety disorders (AOR = 1.53, 95% CI: 1.12–2.10) and
major depression (AOR = 1.63, 95% CI: 1.19–2.22) in demographic models with similar levels in the deployment
models but generally failed to retain statistical signiﬁcance
with the addition of combat exposure in model 3 (poor physical
health: AOR = 1.07, 95% CI: 0.87–1.31; PTSD: AOR = 1.14,
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TABLE 3
Results of multivariable regression relationship between each of six health outcomes and antimalarial use while controlling for sociodemographic
and military service variables
Health outcomes†
Antimalarial, model*

SF12—composite
mental health score

Any antimalarial
Model 1:
1.39 (1.29–1.49)‡
demographics
Model 2:
1.30 (1.14–1.33)‡
demographics +
deployment
Model 3:
1.02 (0.94–1.11)
demographics,
deployment +
combat exposure
Chloroquine
Model 1:
1.33 (1.05–1.70)‡
demographics
Model 2:
1.30 (1.03–1.66)‡
demographics +
deployment
Model 3:
1.15 (0.88–1.50)
demographics,
deployment +
combat exposure
Doxycycline
Model 1:
1.21 (1.07–1.37)‡
demographics
Model 2:
1.11 (0.98–1.26)
demographics +
deployment
Model 3:
0.96 (0.83–1.09)
demographics,
deployment +
combat exposure
Meﬂoquine
Model 1:
1.06 (0.82–1.36)
demographics
Model 2:
0.97 (0.75–1.25)
demographics +
deployment
Model 3:
0.87 (0.66–1.14)
demographics,
deployment +
combat exposure
Primaquine
Model 1:
0.98 (0.64–1.49)
demographics
Model 2:
0.93 (0.61–1.43)
demographics +
deployment
Model 3:
0.74 (0.46–1.18)
demographics,
deployment +
combat exposure
Meﬂoquine + any other antimalarial
Model 1:
1.22 (0.99–1.51)
demographics
Model 2:
1.13 (0.91–1.40)
demographics +
deployment
Model 3:
0.92 (0.73–1.15)
demographics,
deployment +
combat exposure
Any other antimalarial (s)
Model 1:
1.12 (0.93–1.34)
demographics
Model 2:
1.06 (0.87–1.27)
demographics +
deployment

SF12—composite
physical health score

PTSD

Thoughts of death/
self-harm

Other anxiety

Major depression

1.23 (1.14–1.32)‡

1.83 (1.64–2.04)‡

1.31 (1.16–1.47)‡

1.56 (1.38–1.76)‡

1.45 (1.28–1.65)‡

1.32 (1.22–1.42)‡

1.69 (1.51–1.90)‡

1.35 (1.19–1.53)‡

1.51 (1.33–1.73)‡

1.43 (1.25–1.63)‡

1.08 (0.99–1.18)

1.07 (0.94–1.22)

0.97 (0.85–1.12)

1.04 (0.90–1.20)

–

1.20 (0.94–1.53)

1.23 (0.86–1.76)

1.24 (0.84–1.83)

0.80 (0.52–1.23)

0.98 (0.64–1.50)

1.22 (0.95–1.55)

1.18 (0.82–1.68)

1.24 (0.84–1.82)

–

0.96 (0.63–1.47)

1.15 (0.88–1.50)

0.89 (0.60–1.33)

0.94 (0.62–1.42)

0.66 (0.40–1.06)

–

0.96 (0.84–1.09)

1.38 (1.15–1.65)‡

1.13 (0.91–1.40)

1.10 (0.88–1.36)

1.10 (0.88–1.38)

1.00 (0.87–1.14)

1.22 (1.02–1.47)‡

1.13 (0.91–1.40)

1.02 (0.82–1.28)

1.04 (0.83–1.31)

0.91 (0.79–1.04)

0.96 (0.79–1.15)

0.87 (0.69–1.09)

0.85 (0.67–1.07)

0.84 (0.66–1.06)

0.93 (0.72–1.22)

0.97 (0.66–1.44)

1.36 (0.92–2.01)

0.97 (0.64–1.48)

0.86 (0.54–1.36)

0.97 (0.74–1.27)

0.86 (0.58–1.27)

1.36 (0.92–2.01)

0.91 (0.59–1.38)

0.81 (0.51–1.29)

0.96 (0.73–1.26)

–

1.21 (0.80–1.82)

0.77 (0.49–1.22)

0.74 (0.46–1.20)

0.63 (0.42–0.95)‡

0.61 (0.27–1.35)

0.87 (0.35–2.09)

0.34 (0.12–0.99)‡

0.52 (0.20–1.34)

0.64 (0.43–0.97)‡

0.56 (0.25–1.24)

0.87 (0.36–2.08)

–

0.50 (0.19–1.29)

0.56 (0.35–0.87)‡

0.48 (0.21–1.10)

0.78 (0.31–1.98)

0.19 (0.06–0.67)‡

0.46 (0.17–1.21)

1.09 (0.88–1.36)

1.63 (1.20–2.20)‡

1.11 (0.77–1.59)

1.63 (1.17–2.27)‡

1.36 (0.95–1.95)

1.13 (0.91–1.41)

1.45 (1.07–1.97)‡

1.10 (0.77–1.59)

1.53 (1.10–2.14)‡

1.30 (0.90–1.85)

1.00 (0.80–1.26)

1.09 (0.79–1.50)

0.91 (0.62–1.33)

–

–

1.23 (1.02–1.49)‡

1.63 (1.24–2.13)‡

1.42 (1.03–1.96)‡

1.53 (1.12–2.10)‡

1.63 (1.19–2.22)‡

1.26 (1.04–1.53)‡

1.51 (1.15–1.98)‡

1.42 (1.03–1.96)‡

1.47 (1.07–2.01)‡

1.57 (1.15–2.16)‡

(continued)
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TABLE 3
Continued
Health outcomes†
Antimalarial, model*

Model 3:
demographics,
deployment +
combat exposure

SF12—composite
mental health score

SF12—composite
physical health score

PTSD

Thoughts of death/
self-harm

Other anxiety

Major depression

0.92 (0.75–1.13)

1.07 (0.87–1.31)

1.14 (0.86–1.52)

–

1.09 (0.78–1.52)

1.20 (0.86–1.68)

CI = conﬁdence interval; PTSD = post-traumatic stress disorder; SF-12 = twelve-item short form.
* Adjusted odds ratios (95% CI); (–) = interaction.
† Model 1 = all independent variables except deployment and combat intensity; model 2 = all independent variables except combat intensity; model 3 = all independent variables (includes
deployment and combat intensity). We modeled the odds of having a score fall below the U.S. mean vs. the odds of having a score above the U.S. mean when the SF-12 composite scores were used
as outcome variables. When PTSD, thoughts of death/self-harm, other anxiety, and major depression were used as outcome variables, we modeled the odds of having the condition vs. the odds of
not having the condition. N’s for the logistic regressions ranged from 14,813 to 19,106 depending on which outcomes and sets of independent variables were being examined.
‡ 95% CI does not contain 1.0.

95% CI: 0.86–1.52; other anxiety: AOR = 1.09, 95% CI:
0.78–1.52; major depression: AOR = 1.20, 95% CI: 0.86–1.68)
(Table 3). Thoughts of self-harm and death were an exception
to this pattern for the nondeployed where the odds of selfharm/death among users were more than three times the odds
among nonusers in model 3 (AOR = 3.14, 95% CI: 1.24–7.94)
(Table 4).
Primaquine use was weakly, but signiﬁcantly, associated with
poor physical health (SF-12; AOR = 0.63, 95% CI: 0.42–0.95) and
with a positive screen for other anxiety disorders (AOR = 0.34,
95% CI: 0.12–0.99) (Table 3). Generally, similar reductions to
estimates with concomitant losses in signiﬁcance for primaquine
were found for models 2 and 3 after adjusting for deployment
and combat exposure. Exceptions included the estimate for
models 2 and 3 for overall physical health (AOR = 0.64, 95% CI:
0.43–0.97 and AOR = 0.56, 95% CI: 0.35–0.87, respectively);
model 3, other anxiety (AOR = 0.19, 95% CI: 0.06–0.67) (Table 3);
and the AOR representing the association between primaquine
use and anxiety among the deployed in model 2 (AOR = 0.14,
95% CI: 0.03–0.60) (Table 4).
Associations between health outcome and antimalarial drug
differed signiﬁcantly when stratiﬁed by deployment (Table 4).
The AORs found among the nondeployed were far lower than
those found for veterans deployed to Iraq or Afghanistan for
major depression and its association with antimalarial use
(chloroquine, AOR = 0.13, 95% CI: 0.18–0.88; any antimalarial
use, AOR = 0.62, 95% CI: 0.42–0.90) (model 3), and for anxiety
and chloroquine use (AOR = 0.26, 95% CI: 0.08–0.86) (model 2).
Table 5 provides weighted prevalence estimates of each of
the six outcomes stratiﬁed by combat exposure intensity
score (0, 1, 2, or 3) among the deployed. The prevalence of
each outcome increases among antimalarial users with increasing combat intensity score. For the overall MH score, the
prevalence of a score below the U.S. mean among users with a
combat exposure intensity score of 0 (lowest intensity) was
32.5 that increased to 65.8 for those with a score of 3 (highest
intensity). Prevalence of a score below the U.S. mean ranged
from 31.3 to 49.7 for the overall physical health score, from 3.1
to 32.5 for PTSD, from 4.6 to 17.7 for thoughts of death/selfharm, from 2.7 to 20.4 for other anxiety, and from 3.8 to 18.0 for
depression. This positive trend was also observed among
those who did not report antimalarial use.
DISCUSSION
This study surveyed a large population-based sample of
deployed and nondeployed veterans about use of antimalarial

agents and assessed health indices vulnerable to medication
side effects. The ﬁndings suggest that there is a burden of MH
symptoms across the surveyed population, with a greater
burden among the OEF/OIF deployed, regardless of the antimalarial medication reported. Although there appeared to be
signiﬁcant elevated odds of poor mental and physical health
outcomes among those who reported antimalarial use relative
to nonusers, once the effect of combat exposure was adjusted
for, signiﬁcant relationships generally diminished, implying
that in this large population-based sample, it is the effect of
combat exposure that is driving the MH burden, not the exposure to antimalarial medication.
The highest prevalence of PTSD and other anxiety disorders
was reported by deployed veterans who endorsed use of
meﬂoquine plus other antimalarials. The highest prevalence of
thoughts of death or self-harm among the deployed was reported by the meﬂoquine group. Other anecdotal reports and
research indicated that neuropsychiatric side effects of
meﬂoquine are a risk,3,25–32,40,43–46,56 but more so for those
with prior MH issues, 29,33,34 ﬁrst-time users, 31 and
women1,27,31,33,57–59 that is probably because of their lower

TABLE 4
Interactions from multivariable logistic regression, stratiﬁed by deployment status
Antimalarial/outcome association,
model

Any antimalarial use/major
depression, model 3†
Chloroquine/anxiety,
model 2†
Chloroquine/major
depression, model 3†
Primaquine/anxiety,
model 2†
Meﬂoquine/post-traumatic
stress disorder, model 3†
Meﬂoquine plus§/anxiety,
model 3
Meﬂoquine plus§/major
depression, model 3†
Other antimalarial(s)/
thoughts of death/selfharm, model 3†

Deployed*

Nondeployed*

1.09 (0.93–1.28)

0.62 (0.42–0.90)‡

0.97 (0.60–1.55)

0.26 (0.08–0.86)‡

0.95 (0.59–1.54)

0.13 (0.18–0.88)‡

0.14 (0.03–0.60)‡

1.45 (0.35–6.08)

0.74 (0.49–1.10)

–

1.26 (0.88–1.81)

–

1.11 (0.76–1.64)

–

1.06 (0.75–1.50)

3.14 (1.24–7.94)‡

CI = conﬁdence interval.
* Adjusted odds ratios (95% CI); (–) = estimates not reported because odds ratios and
associated 95% CIs are smaller than 0.001.
† Model 2 = all independent variables except combat intensity; model 3 = all independent
variables (includes deployment and combat intensity).
‡ 95% CI does not contain 1.0.
§ Meﬂoquine and other antimalarial(s) reported.
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TABLE 5
OEF/OIF combat exposure intensity and antimalarial drug use among veterans who were deployed (N = 12,456), selected health outcomes: National
Health Study for a New Generation of U.S. Veterans
Selected health outcomes*

OEF/OIF CE,*† antimalarial drugs
received during military service*

CE = 0
Antimalarial drug use
Meﬂoquine
Chloroquine
Doxycycline
Primaquine
Meﬂoquine + “X”k
Other antimalarials
Type not speciﬁed
No use
CE = 1
Antimalarial Drug Use
Meﬂoquine
Chloroquine
Doxycycline
Primaquine
Meﬂoquine + “X”
Other antimalarials
Type not speciﬁed
No use
CE = 2
Antimalarial drug use
Meﬂoquine
Chloroquine
Doxycycline
Primaquine
Meﬂoquine + “X”
Other antimalarials
Type not speciﬁed
No use
CE = 3
Antimalarial drug use
Meﬂoquine
Chloroquine
Doxycycline
Primaquine
Meﬂoquine + “X”
Other antimalarials
Type not speciﬁed
No use

All (N = 12,456)‡

SF-12 mental health score
(below U.S. mean)

SF-12 physical health score
(below U.S. mean)

PTSD

Thoughts of death/
self-harm

Other
anxiety

Major
depression

(%)

(%)

(%)

(%)

(%)

(%)

(%)

3,736 (28.7)
1,244 (16.7)
61 (4.6)
47 (3.0)
222 (18.6)
18 (1.3)
48 (3.8)
85 (6.3)
763 (62.4)
2,492 (42.3)
2,913 (22.6)
1,438 (20.0)
73 (4.5)
59 (3.8)
271 (19.6)
18 (1.3)
76 (4.6)
129 (8.0)
812 (58.3)
1,475 (25.4)
3,128 (24.7)
2,049 (29.8)
93 (3.8)
88 (3.8)
430 (20.8)
35 (4.5)
149 (6.5)
158 (6.8)
1,096 (55.8)
1,079 (18.9)
2,513 (24.0)
1,869 (33.5)
78 (4.2)
76 (3.4)
387 (21.9)
27 (1.2)
152 (7.7)
152 (6.9)
997 (54.6)
644 (13.3)

35.7
32.5
27.3
47.3
34.8
39.9
34.7
16.0
32.8
37.2
45.6
43.3
49.4
48.1
40.9
17.0
36.1
37.1
45.4
47.7
59.1
59.0
56.5
54.0
59.1
51.2
59.4
48.4
60.9
59.3
64.7
65.8
61.6
72.6
62.8
45.2
58.4
67.8
68.2
61.6

30.8
31.3
29.4
32.4
26.6
37.3
26.5
37.1
32.3
30.6
37.1
38.3
36.8
49.5
34.1
12.1
38.5
30.7
40.7
36.0
45.3
47.1
32.3
51.6
42.8
41.5
43.0
47.6
50.3
42.1
48.4
49.7
50.1
60.6
44.8
19.8
50.9
55.5
50.7
44.8

3.6
3.1
6.9
3.3
3.8
–§
6.7
0.6
2.7
3.8
8.2
7.2
2.7
3.3
6.3
6.7
6.6
1.0
9.0
9.1
18.7
19.3
10.1
17.9
16.1
6.2
12.7
16.6
22.8
17.8
31.9
32.5
29.8
37.2
31.7
11.5
33.5
38.3
32.4
30.1

4.3
4.6
1.6
6.3
5.8
–
10.9
3.0
4.2
4.2
7.0
6.9
14.8
3.2
7.4
2.2
3.8
2.2
7.3
7.2
12.6
12.2
14.4
8.0
10.2
2.1
7.8
9.2
14.2
13.3
18.2
17.7
18.9
26.1
15.1
17.6
15.3
21.8
18.0
19.5

3.3
2.7
2.1
1.6
3.7
–
9.8
0.6
2.4
3.6
6.3
5.0
9.6
4.4
4.5
–
5.6
0.7
5.6
7.4
13.3
14.4
9.9
10.7
12.8
3.7
12.5
12.4
16.4
11.5
20.2
20.4
16.2
17.6
16.9
–
22.2
25.0
21.9
19.5

4.0
3.8
3.4
6.5
3.8
–
9.8
1.7
3.6
4.1
6.3
5.9
8.4
1.8
5.2
–
6.0
3.4
6.6
6.7
12.1
12.7
8.4
9.3
10.1
9.0
10.7
9.8
14.9
11.0
18.3
18.0
14.2
21.8
14.7
–
16.9
24.5
19.1
19.2

CE = combat exposure; PTSD = post-traumatic stress disorder; OEF = Operation Enduring Freedom (Afghanistan); OIF = Operation Iraqi Freedom (Iraq); SF-12 = twelve-item short form.
* Self-reported.
† Combat exposure intensity, deﬁned from 0 (no combat exposure) to 3 (highest intensity) and was based on responses to three questions from the study questionnaire: 1) “Did you ever feel that
you were in great danger of being killed?” 2) “Did you see anyone wounded, killed, or dead?” 3) “Were you engaged in directed combat where you discharged your weapon?”.
‡ Of the 19,487 respondents in analytical sample, 12,456 were deployed. Of these, 166 had missing on combat exposure.
§ Cell count is 0.
k X = 1 or 2 other antimalarials reported.

body weight60; still some contend that serious side effects
from meﬂoquine are rare.2,61–64
Other than the categories of any antimalarials and other
antimalarials in our analysis, only doxycycline and meﬂoquine
plus any other antimalarial showed the greatest associations
with PTSD and with PTSD and other anxiety disorders, respectively, before the addition of combat exposure to the
models. However, with the inclusion of deployment and
combat exposure to regression models, the ORs associated
with antimalarial use became attenuated for all health outcomes. Consistent across most health outcomes and all antimalarial medications included in the study was the absence
of statistically signiﬁcant elevated associations when combat
exposure was included in the model. This suggests that
combat and deployment experiences are potent factors associated with MH outcomes, even in the presence of other

recognized hazards such as medication side effects that may
contribute to morbidity. The positive trend that was observed
when the mental and physical health outcomes were stratiﬁed
by combat score intensity supports this ﬁnding. These ﬁndings do not invalidate the previous anecdotal reports or
studies that indicate that neuropsychiatric side effects of
meﬂoquine are a risk. Although these ﬁndings suggest that
veterans’ MH morbidity is not a result of meﬂoquine or other
chemoprophylactic agents, further research is warranted to
better understand this relationship.
The associations identiﬁed for many of the other antimalarial
agents in this analysis were not followed by primaquine. It
generally had the lowest prevalence of all health indices and
the lowest association with any of the health outcomes. Although primaquine had the second highest prevalence for
other anxiety disorders among the nondeployed, we were
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unable to conﬁrm the existence of other studies that supported this ﬁnding. Primaquine also had the lowest prevalence
for PTSD, thoughts of self-harm, and major depression among
both the deployed and nondeployed compared with the other
medications examined. This ﬁnding is consistent with other
studies supporting its limited impact on neuropsychiatric
function.23 Kolifarhood et al.65 conducted a meta-analysis and
concluded that primaquine had generally equivalent or lesser
neuropsychiatric effects than other antimalarial medications.
A study of 203 Australian military personnel66 showed no signs
of neuropsychiatric effects, except for headache that was
reported to be mild in severity and transient. A study of leisure
travelers to Ethiopia included 106 people who were prescribed
primaquine, one participant withdrew because of GI complaints.67 However, in a randomized, placebo-controlled trial,
the risk of headache (relative risk = 0.62, P < 0.05) was signiﬁcantly higher among those treated with primaquine than for
those given a placebo.68
The association between reported use of other antimalarial(s)
and thoughts of death/self-harm among the nondeployed is interesting, both in magnitude and signiﬁcance (AOR = 3.14, 95%
CI: 1.24–7.94). We did not expect to ﬁnd this. Although these
individuals did not deploy to OEF/OIF, they may have been
stationed in other places where malaria is endemic (Africa,
Central America, and South America), requiring the use of antimalarial medication. Although our survey asked about common
antimalarial medications, the list was not exhaustive. There
are three common antimalarial medications that were not speciﬁcally queried in our survey, including Qualaquin® (quinine)
(Mutual Pharmaceutical Company, Inc., Philadelphia, PA),
Plaquenil® (hydroxychloroquine) (Concordia Pharmaceuticals
Inc., Oakville, Ontario, Canada), and Malarone® (atovaquone and
proguanil) (GlaxoSmithKline, Philadelphia, PA), all of which have
psychiatric side effects.46,69 It is possible that nondeployed
servicemembers serving in other malaria-endemic parts of the
world took these antimalarials and experienced psychiatric side
effects, or experienced other events during their time in the military that would have resulted in a poor MH outcome.
The study has several strengths including the use of validated scales measuring health outcomes of concern.49,50,52
This is the ﬁrst population-based study of OEF/OIF veterans to
examine the long-term effects of antimalarial use on mental
and physical health outcomes. The stratiﬁed sample design
was used to obtain representative estimates of several population subgroups of major interest that included the branches
of the military; the reserve, National Guard and active duty;
and deployed and nondeployed service personnel. Survey
responses were weighted to reduce bias resulting from nonresponse and misclassiﬁcation of deployment status54 and
women were oversampled to maximize their inclusion in the
study.41 The stratiﬁed complex survey design served to reduce variance (increase precision) of the point estimates
generated for subgroups of this population.
The study relies on self-reported data for type of antimalarial medication, which is acknowledged as a weakness.
The number of individuals reporting speciﬁc medications
was sufﬁcient to conduct robust analyses, but 23.5% of
individuals reported use of antimalarials without specifying
type and 61.4% comprised individuals who reported no use.
Health indices only measured current symptoms, not
symptoms experienced historically or potentially related to
medications. The absence of data regarding side effects

related to medication use is a shortcoming; however, the
objective of this study was to assess chronic impact on
neuropsychiatric symptoms, not all the side effects of
medication use, most of which are acute in nature.35
Moreover, we have no data on drug compliance, so we are
unable to determine whether outcomes assessed result
from taking medications as prescribed. There is no measure
of deployment duration among the deployed group to ascertain if multiple opportunities to use antimalarials was
associated with reporting multiple drugs and increased
exposure to both combat and traumatic events. We also did
not collect information on antimalarial administration, so we
have no data on whether reports of “combinations” involved
medications being taken separately or at the same time.
Another limitation of this analysis relates to the time period of
the questions used to assess exposure and outcomes. Exposure
to antimalarial medication was queried during military service
and not speciﬁc to an OEF/OIF deployment. Therefore, it is not
possible to determine if the exposure to antimalarial medication
occurred before exposure to combat. Post-traumatic stress
disorder was assessed in the past 4 weeks (from date the survey
was ﬁlled out), as was anxiety. Major depressive disorder and
self-harm were assessed in the past 2 weeks. The physical and
mental component of the SF-12 assesses experiences in the
past 4 weeks. Combat intensity was assessed during any of a
respondent’s deployments, and not speciﬁcally to OEF/OIF
deployments (as servicemembers often have multiple deployments during multiple wars). In addition, although the MH outcomes are measured in the past 2 or 4 weeks, it is not possible to
determine when the respondents began experiencing the MH
outcomes and if it was before or after exposure to antimalarial
medication. While these analyses can determine association, temporality cannot be established.
These ﬁndings do not invalidate the risks associated with
meﬂoquine use, including the potential for acute or long-term
neuropsychiatric effects in certain individuals, such as those
with a history of psychiatric illness. Health-care providers,
those serving veterans, and those serving the general population need to carefully consider the potential antecedent
factors and precipitating events, including combat exposure,
when seeking to understand and diagnose psychiatric morbidity or neuropsychiatric effects known to be associated with
meﬂoquine use. Careful assessment of deployment history
and medication administration should accompany the patient
history during clinical evaluation.
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